Scilex Holding Company Overview
SCLX market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 1.69
- H
- 1.69
- L
- 1.67
- C
- 1.67
- Vol
- 544.00
Daily history from Mar 17, 2021
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $1.69
- Previous Close
- $1.83
- Day High
- $1.69
- Day Low
- $1.67
- 52 Week High
- $16.34
- 52 Week Low
- $1.67
- 7 Day Return
- -19.90%
- 30 Day Return
- -59.66%
- 90 Day Return
- -76.21%
- 1 Year Return
- -85.45%
- Daily Notional Volume
- $908.5 Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$32.51 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.93 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,414.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.83 – $27.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $13M · P/B 15.56 · P/S 0.41.